|
Mutation Information
|
Mutation Site
|
M204I |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.L80I+rt.L80V+rt.M204I;rt.L180M+rt.M204I;rt.L180M+rt.L80I+rt.L80V+rt.M204I |
|
Genotype/Subtype
|
A;B;C;D |
|
Relevant Drug
|
lamivudine (LAM) |
Literature Information
|
PubMed PMID
|
17438047
|
|
Published Year
|
2007 |
|
Journal
|
Antimicrobial agents and chemotherapy |
|
Title
|
The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. |
|
Author
|
Warner N,Locarnini S,Kuiper M,Bartholomeusz A,Ayres A,Yuen L,Shaw T |
|
Evidence
|
Mutations that result in the replacement of the methionine at position 204 of the deoxynucleoside triphosphate-binding site of the hepatitis B virus (HBV) reverse transcriptase (rt) by isoleucine, valine, or (rarely) serine (rtM204I/V/S) confer high-level resistance to LMV but reduce replication efficiency.
|
|
|
HBV Mutation Detail Information